Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

5(71.4%)

Phase 1

1(14.3%)

N/A

1(14.3%)

7Total

Phase 2(5)

Phase 1(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04230356Phase 2Recruiting

Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant

Role: collaborator

NCT02048332Phase 1Recruiting

Donor-Derived Viral Specific T-cells (VSTs)

Role: collaborator

NCT04331275Phase 2Active Not Recruiting

Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant

Role: collaborator

NCT03883906Phase 2Completed

Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant

Role: collaborator

NCT04406064Phase 2Withdrawn

Viral Specific T-cells for Treatment of COVID-19

Role: collaborator

NCT01856582Phase 2Terminated

CD34+ Stem Cell Infusion to Augment Graft Function

Role: collaborator

NCT02274064Not ApplicableCompleted

Motivating Type O- Blood Donors to Return

Role: collaborator

All 7 trials loaded